VAMOX Co-Amoxiclav 400mg / 57mg per 5mL Powder for Suspension 70mL
We recognize that purchasing medications can be a deeply personal matter. To respect your privacy, we ensure that all orders are packaged discreetly, with no indication of the contents on the packaging. This means that even our couriers remain unaware of the package contents.
Furthermore, we uphold strict confidentiality standards. We guarantee that your order information will never be disclosed to any third party. Your trust is paramount to us, and we are committed to safeguarding your privacy at every step of the process. Our dedication to discretion and confidentiality is part of our unwavering commitment to you, our valued customer.
Features
- Co-Amoxiclav
Description
Indications/Uses
Susceptible organisms are β-lactamase producing strains of Haemophilus influenzae and Moraxella (Branhamella) catarrhalis which cause lower respiratory infections; β-lactamase producing strains of Haemophilus influenzae and Moraxella (Branhamella) catarrhalis causing otitis media and sinusitis; and β-lactamase producing strains of Staphyloccocus aureus, Escherichia coli, Klebsiella spp and Enterobacter spp which cause skin and skin structure infections.
Dosage/Direction for Use
Administration
Contraindications
Special Precautions
Therefore caution should be exercised when Co-amoxiclav is administered to a nursing woman.
Adverse Reactions
Co-amoxiclav possesses the characteristic low toxicity of the penicillin group at antibiotics. Periodic assessment of organ system functions, including renal, hepatic and hematopoietic function, is advisable during prolonged therapy. A high percentage of patients with mononucleosis who received ampicillin develop a skin rash. Thus, ampicillin class antibiotics are excreted in milk; Therefore caution should be exercised when Co-amoxiclav is administered to a nursing woman.
Drug Interactions
Hormonal contraceptives: decreased contraceptive efficacy.
Probenecid: decreased renal excretion and increased blood level of amoxicillin.
Caution For Usage
To make up to 10 mL, shake bottle to loosen powder, then add 9.2 mL of distilled water and shake well to suspend powder. Keep reconstituted powder under refrigeration (2°C - 8°C). Discard after 10 days.
For 250 mg/62.5 mg/5 mL Powder for Suspension: To make up to 60 mL, shake bottle to loosen powder, then add 53 mL of distilled water and shake well to suspend powder. Keep reconstituted powder under refrigeration (2°C - 8°C). Discard after 10 days.
To make up to 10 mL shake bottle to loosen powder, then add 8.5 ml of distilled water and shake well to suspend powder. Keep reconstituted powder under refrigeration (2°C - 8°C). Discard after 10 days.
Instructions and Special Precautions for Handling and Disposal: Do not freeze.
After reconstitution to form an oral suspension, this medicine should only be used up to 7 days from the dispensing data stated on the label.
Medicines should not be disposed of via wastewater or household waste. Ask the pharmacist how to dispose of medicines no longer use.